Cargando…
Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma
BI‐ALCL is a rare CD30+ T‐cell malignancy, which is known to complicate textured breast implants. The CD30‐targeting immunoconjugate, brentuximab vedotin, has been suggested for invasive BI‐ALCL; however, its efficacy for unresectable BI‐ALCL has not been demonstrated. We present a case of unresecta...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510013/ https://www.ncbi.nlm.nih.gov/pubmed/31110735 http://dx.doi.org/10.1002/ccr3.2142 |